AbbVie presents the most strategically complex and commercially compelling target of the three pharma companies analysed to date. Its portfolio spans five distinct therapeutic pillars — Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care — with $56.3 billion in 2024 net revenues. Unlike GSK (dominated by biologics) or Lilly (dominated by metabolic drugs), AbbVie has two small-molecule franchises with strong published P-gp/BCRP substrate evidence: ibrutinib (Imbruvica) in oncology and upadacitinib (Rinvoq) in immunology. Critically, AbbVie is also building a major CNS neuroscience franchise (Vraylar, tavapadon, emraclidine's successor) — and its new Parkinson's pipeline asset tavapadon depends on CNS penetration as a core mechanism, where elacridar co-administration could materially enhance striatal D1/D5 receptor occupancy.
Our lead recommendation for AbbVie is Imbruvica (ibrutinib) + Elacridar for Primary CNS Lymphoma (PCNSL) — a rare, aggressive, uniformly fatal malignancy where ibrutinib has already demonstrated 77% response rates in relapsed/refractory PCNSL in Phase I data, and where P-gp-mediated BBB efflux is the primary pharmacological barrier to converting these promising signals into durable responses. The combination is supported by ironclad pharmacology, an existing clinical dataset, and a clear regulatory pathway. A secondary high-conviction programme is Rinvoq + Elacridar for CNS inflammation in neuropsychiatric lupus — where upadacitinib is a confirmed P-gp/BCRP substrate and CNS JAK signalling is a validated pathological target.
The AbbVie Unique Angle — Three Simultaneous Opportunities in Different Therapeutic Areas: GSK had one clear lead (niraparib/GBM). AbbVie has three simultaneously compelling opportunities — ibrutinib in CNS lymphoma (oncology), upadacitinib in neuropsychiatric lupus (immunology/CNS), and venetoclax in AML (safety/dose reduction). This diversification is commercially attractive but requires prioritisation. The CNS lymphoma story is the most compelling because ibrutinib already has clinical proof of principle in PCNSL and the pharmacological reason for incomplete responses (P-gp efflux at BBB) is well-established.
| Drug (Brand) | Class / Indication | 2024 Sales | LOE | P-gp / BCRP Substrate? | Combination Rationale | Type | Score | Projected Combo Peak Sales |
|---|---|---|---|---|---|---|---|---|
| Humira adalimumab |
Immunology — anti-TNF mAb; RA, IBD, psoriasis (biosimilar erosion phase) | $8.99bn | Genericised (biosimilar 2023) | Monoclonal antibody — not a P-gp/BCRP substrate | No pharmacological rationale. Humira is in biosimilar erosion; any combination deal would face the wrong commercial trajectory | N/A | LOW | No opportunity |
| Rinvoq ★ upadacitinib |
Immunology — JAK1 inhibitor; RA, PsA, AS, UC, CD, atopic dermatitis, GCA (9 indications) | $5.97bn | ~2030–2032 | YES — Confirmed in prescribing information. Upadacitinib is explicitly stated as a P-glycoprotein and BCRP substrate in the Australian TGA prescribing information and EMA assessment reports. The clinical relevance is noted as uncertain for peripheral indications, but for CNS targets, this is critical | HIGH-CONVICTION SECONDARY PROGRAMME. Upadacitinib's JAK1 selectivity makes it uniquely interesting for neuropsychiatric lupus and CNS inflammatory conditions. The BBB normally excludes JAK inhibitors — but CNS autoimmune inflammation (neuropsychiatric SLE, CNS vasculitis) represents an unmet need where CNS JAK signalling drives pathology. Elacridar co-administration would increase CNS exposure of upadacitinib substantially. AbbVie is already developing Rinvoq for SLE (systemic) — a CNS-enhanced formulation could create a neuroprotective SLE indication that commands premium pricing. Also relevant: resistance to upadacitinib may involve P-gp upregulation in inflamed tissue, and elacridar could re-sensitise partially-resistant patients | BOTH | HIGH | $1.2–2.0bn (neuropsychiatric SLE: ~$180k/yr indication; CNS autoimmune space growing rapidly) |
| Skyrizi risankizumab |
Immunology — anti-IL-23 mAb; psoriasis, PsA, Crohn's, UC | $11.72bn | ~2031+ | Monoclonal antibody — not a P-gp substrate | No rationale. Biologics are not P-gp substrates. Skyrizi is AbbVie's crown jewel; no elacridar angle | N/A | LOW | No opportunity |
| Imbruvica ★★ ibrutinib |
Oncology — BTK inhibitor; CLL, MCL, WM, MZL, GVHD, PCNSL (investigational) | $3.35bn | Compound patent 2027; generic entry no earlier than 2032 | YES — Confirmed. Published molecular pharmacology (ACS Mol Pharm 2018): ABCB1 (P-gp) markedly restricts ibrutinib brain penetration in mice. Abcb1-knockout mice showed 4.5-fold increase in ibrutinib brain-to-plasma ratio. Combined ABCB1/ABCG2 knockout increased ratio 5.9-fold. Elacridar would replicate knockout pharmacology in WT animals | ★★ LEAD PROGRAMME. Ibrutinib has already demonstrated 77% overall response rate in Phase I relapsed/refractory PCNSL patients — far exceeding its response rates in systemic B-cell malignancies. The BBB is the primary reason ibrutinib's CNS responses are incomplete and non-durable — insufficient CNS drug concentration leads to partial responses and eventual CNS breakthrough. Elacridar co-administration would achieve complete transporter saturation at the BBB, increasing ibrutinib brain concentration to levels seen in P-gp knockout mice (4.5–5.9-fold increase). This converts partial PCNSL responses to complete responses, and prevents CNS breakthrough. PCNSL is uniformly fatal (OS ~1–2 yrs), FDA-designated rare disease, and commands highest-tier pricing. This is the most commercially and scientifically compelling combination in the AbbVie portfolio | BOTH | HIGH | $800m–1.3bn (PCNSL ~1,500–3,500 cases/yr in US+EU; rare disease pricing $200–300k/yr; plus secondary CNS lymphoma indication ~15k cases/yr globally) |
| Venclexta venetoclax |
Oncology — BCL-2 inhibitor; CLL/SLL, AML | $2.58bn | ~2026–2028 (with generic challenges ongoing) | YES — Confirmed. Both venetoclax and its major plasma metabolite M27 are confirmed substrates for P-glycoprotein (P-gp) and BCRP (published PK review, Clinical and Translational Science 2024). Additionally, venetoclax has notoriously variable oral bioavailability (~15-fold inter-patient variation in apparent oral clearance). P-gp overexpression leads to reduced antiproliferative venetoclax effects in MDR cell lines | SAFETY-DRIVEN COMBINATION. Venetoclax's key clinical challenge is tumour lysis syndrome (TLS) — driven by rapid, high-level BCL-2 inhibition. The current dosing ramp-up over 5 weeks is entirely a safety management strategy. Elacridar could theoretically enable a lower starting dose of venetoclax with enhanced bioavailability and more predictable PK — a lower-dose, elacridar-enabled venetoclax formulation could reduce TLS risk while maintaining efficacy, potentially eliminating the 5-week ramp-up and enabling outpatient dosing. However, the DDI complexity (venetoclax is also a CYP3A4 substrate; elacridar's effect on CYP3A4 could further complicate exposure) makes this a technically complex programme requiring extensive DDI characterisation | SAFETY ↑ | MEDIUM | $500–800m (AML outpatient dosing premium; but LOE pressure limits runway) |
| Elahere mirvetuximab soravtansine-gynx |
Oncology — FRα-targeting ADC + DM4 payload; platinum-resistant ovarian cancer | $479m (partial year from Feb 2024) | ~2033+ | ADC with DM4 (maytansinoid) payload. Maytansinoids are tubulin inhibitors; their intracellular P-gp efflux after linker cleavage is a known resistance mechanism in ADC biology | Similar to GSK's Blenrep analysis — once the ADC is internalised and the DM4 payload is released intracellularly, P-gp efflux can remove the active cytotoxin before it kills the cell. Elacridar could inhibit intracellular P-gp efflux of DM4, re-sensitising FRα+ tumour cells that have upregulated P-gp as a DM4 resistance mechanism. This is particularly relevant as patients who progress on Elahere — a defined 2nd-line opportunity. Speculative but scientifically plausible; in vitro combination study required | EFFICACY ↑ | LOW | $300–500m (2nd-line after Elahere resistance; companion dx required) |
| Epkinly epcoritamab |
Oncology — CD3×CD20 bispecific antibody; DLBCL | ~$160m | ~2035+ | Bispecific antibody — not a P-gp substrate. Large molecule | No pharmacological rationale for bispecific antibodies | N/A | LOW | No opportunity |
| Vraylar cariprazine |
Neuroscience — D3/D2 partial agonist; schizophrenia, bipolar I, bipolar depression, MDD | $3.27bn | ~2028–2029 | Cariprazine: small molecule atypical antipsychotic. CNS drugs typically require good BBB penetration by design — cariprazine was optimised for CNS exposure. Transporter substrate data limited but class effect suggests potential P-gp sensitivity | Atypical antipsychotics with partial D3/D2 agonism that are P-gp substrates (e.g., aripiprazole is a known P-gp substrate) suggest the class may benefit from P-gp inhibition for CNS penetration. If cariprazine brain exposure is partially P-gp limited, elacridar could enhance striatal D3 receptor occupancy — potentially improving efficacy at lower doses. However, cariprazine's existing CNS penetration appears clinically adequate; this is a lower-priority hypothesis without published substrate evidence. Would require new transporter characterisation study | EFFICACY ↑ | LOW | $200–400m (marginal dose-reduction benefit; near LOE limits runway) |
| Tavapadon ★ ABBV-951 / Cerevel |
Pipeline — D1/D5 selective dopamine partial agonist; Parkinson's disease (NDA submitted 2025) | Pre-revenue (NDA filed) | N/A (new launch) | Tavapadon is metabolised primarily by CYP3A4. Published Phase 1 PK data confirm CYP3A4 dominates clearance (itraconazole co-administration caused 4–5-fold exposure increase). P-gp/BCRP transporter data not yet published in detail, but CYP3A4-metabolised CNS drugs with good oral absorption frequently have co-existing P-gp sensitivity. Full transporter characterisation should be requested from AbbVie's clinical pharmacology team | NOVEL CNS PIPELINE COMBINATION OPPORTUNITY. Tavapadon must penetrate the BBB and reach D1/D5 receptors in the striatum. If tavapadon has any P-gp/BCRP sensitivity at the BBB (as most CNS small molecules do), elacridar co-administration could enhance striatal dopamine receptor occupancy, potentially enabling better motor control at lower tavapadon doses — which directly reduces the dose-dependent cardiovascular side effects that historically killed D1 agonist development. This is a pre-launch asset, meaning a combination study could be initiated immediately and filed as a companion product or lifecycle innovation. The commercial timing is ideal — an elacridar-enabled tavapadon formulation could be the differentiated "next generation" product if the initial launch shows dose-limiting adverse effects | BOTH | MEDIUM | $400–800m (Parkinson's market ~$8bn globally; differentiated CNS-enhanced dosing if initial tavapadon shows dose-limiting AEs) |
| Ubrelvy ubrogepant |
Neuroscience — CGRP receptor antagonist; acute migraine | $1.01bn | ~2031 | Ubrogepant is a CYP3A4 substrate. Published PK data: ubrogepant exposure increases significantly with CYP3A4 inhibitors. P-gp substrate status confirmed for the gepant class — the FDA label warns against use with P-gp inhibitors due to exposure increases | Counterintuitively, elacridar co-administration with ubrogepant would increase ubrogepant exposure — potentially creating a safety concern (over-exposure) rather than a benefit. The FDA label already warns of drug interactions with P-gp inhibitors. This is a contra-indication for elacridar combination. Do not pursue | AVOID | LOW | No opportunity — potential DDI safety concern |
| Qulipta atogepant |
Neuroscience — CGRP receptor antagonist; preventive migraine | $658m | ~2033 | Same gepant class as Ubrelvy — confirmed P-gp/CYP3A4 substrate with dose-exposure warnings in label | Same DDI concern as Ubrelvy — elacridar would increase atogepant exposure unpredictably. Avoid | AVOID | LOW | No opportunity — contra-indicated |
| Botox Therapeutic onabotulinumtoxinA |
Neuroscience — botulinum toxin; chronic migraine, overactive bladder, spasticity, blepharospasm | $3.28bn | N/A (biologic) | Protein toxin (150 kDa) — not a P-gp substrate. Injected delivery; no oral bioavailability or BBB relevance | No rationale. Injectable biologic protein; elacridar mechanism does not apply | N/A | LOW | No opportunity |
| Botox Cosmetic onabotulinumtoxinA |
Aesthetics — botulinum toxin; facial wrinkles, frown lines | $2.74bn | N/A | Same as Botox Therapeutic — injectable protein | No rationale | N/A | LOW | No opportunity |
| Juvederm Collection hyaluronic acid fillers |
Aesthetics — dermal fillers; facial volume, contouring | $1.10bn | N/A | Cross-linked hyaluronic acid gel — not applicable | No rationale | N/A | LOW | No opportunity |
| Mavyret glecaprevir + pibrentasvir |
HCV treatment (pan-genotypic NS3/4A + NS5A inhibitor) | ~$1.4bn | ~2029–2030 | Glecaprevir and pibrentasvir are both confirmed P-gp and BCRP substrates. The Mavyret label explicitly warns of DDIs with P-gp inhibitors due to increased exposure | P-gp inhibition would increase systemic exposure of Mavyret components — but HCV drugs already achieve excellent SVR rates; there is no clinical need to increase exposure and doing so risks adverse events. The DDI would be harmful rather than beneficial for this indication. However, there is an interesting speculative angle: HCV CNS reservoir (neurological complications of HCV) — but this is far too niche and speculative for prioritisation | AVOID | LOW | No opportunity — DDI safety concern |
| Creon pancrelipase |
Gastroenterology — pancreatic enzyme replacement | ~$1.3bn | ~2026 (at risk) | Enzyme replacement — not a transporter substrate | No rationale | N/A | LOW | No opportunity |
| Emraclidine Cerevel — FAILED Phase 2 |
Pipeline (failed Jan 2025) — muscarinic M4 PAM; schizophrenia | Pre-revenue (failed) | N/A (discontinued) | Muscarinic M4 PAM — small molecule CNS drug. Phase 2 failure in two schizophrenia studies. $3.5bn writedown | Emraclidine failed on efficacy, not pharmacokinetics. If failure was partly due to insufficient M4 receptor occupancy from sub-therapeutic CNS exposure, elacridar combination could theoretically rescue the asset. However, Phase 2 failure with two independent studies suggests the primary hypothesis (M4 PAM for schizophrenia) may be wrong, not just drug exposure. Very high risk rescue attempt — not recommended as a priority without detailed analysis of PK/PD from the failed studies | EFFICACY ↑ | LOW | $0–500m (extremely high risk; Phase 2 failure requires full PK/PD analysis before decision) |
| Navitoclax ABT-263 |
Pipeline — BCL-2/BCL-xL inhibitor; myelofibrosis combination (Phase 3 with ruxolitinib) | Pre-revenue | N/A | BCL-2/BCL-xL inhibitor — same class as venetoclax, confirmed P-gp/BCRP substrate. Thrombocytopenia is the major dose-limiting toxicity (BCL-xL inhibition in platelets) | Same safety-driven rationale as venetoclax: P-gp inhibition could improve navitoclax bioavailability allowing dose reduction while maintaining efficacy — potentially reducing the thrombocytopenia that limits navitoclax's clinical use. The combination could enable a lower starting dose that avoids the BCL-xL platelet toxicity threshold while maintaining BCL-2 tumour cell killing. This is an attractive and underexplored safety-driven opportunity with a clear mechanistic logic | SAFETY ↑ | MEDIUM | $300–600m (myelofibrosis market ~$4bn; dose reduction enabling outpatient use is commercially significant) |
| Lutikizumab ABT-981 |
Pipeline — IL-1α/β dual inhibitor; HS, UC, atopic dermatitis (Phase 2/3) | Pre-revenue | N/A | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| ABBV-CLS-484 anti-CD47 |
Pipeline — CD47 "don't eat me" signal inhibitor; oncology (Phase 2) | Pre-revenue | N/A | Antibody/fusion protein — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Pivekimab sunirine PVEK / ImmunoGen ADC |
Pipeline — CD123-targeting ADC; BPDCN, AML (Phase 2/3) | Pre-revenue | N/A | ADC with MMAE payload — MMAE is a confirmed P-gp substrate. Intracellular P-gp efflux of MMAE after ADC internalisation is a documented ADC resistance mechanism | Same ADC resistance reversal logic as Elahere and Blenrep — elacridar could inhibit intracellular P-gp efflux of the MMAE cytotoxin after ADC internalisation in BPDCN/AML cells overexpressing P-gp. BPDCN is an ultra-rare, aggressive haematological malignancy with high P-gp expression. Speculative but pharmacologically sound. In vitro combination study is the appropriate next step | EFFICACY ↑ | LOW | $100–300m (ultra-rare; high pricing but tiny patient population) |
LEAD PROGRAMME · ONCOLOGY · CNS LYMPHOMA · BTK INHIBITION + COMPLETE BBB TRANSPORTER BLOCKADE
The ibrutinib CNS lymphoma story is remarkable and the pharmacology is completely clear. Published peer-reviewed data (ACS Molecular Pharmaceutics, 2018) demonstrate that ABCB1 (P-gp) markedly restricts ibrutinib brain penetration in mice, with 4.5-fold and 5.9-fold increases in brain-to-plasma ratios in P-gp single and dual ABCB1/ABCG2 knockout mice respectively vs wild-type. Elacridar, as a dual P-gp and BCRP inhibitor, would pharmacologically replicate the transporter knockout condition, enabling ibrutinib to achieve full therapeutic CNS concentrations.
The clinical signal in PCNSL is extraordinary but incomplete — and the incompleteness is pharmacologically explicable. A Phase I trial (Soussain et al., Cancer Discovery 2017) showed 77% overall response rate (including 5 complete responses of 13 patients) in relapsed/refractory PCNSL — dramatically higher than ibrutinib's ~70% response rate in systemic CLL/MCL. PCNSL responds better because BTK signalling is especially important in CNS lymphoma biology. But responses are often partial and impermanent — almost certainly because insufficient ibrutinib reaches the CNS at approved doses. Elacridar eliminates this pharmacological ceiling.
PCNSL is a uniquely attractive regulatory target. It is an orphan disease (fewer than 5,000 cases/yr in US+EU), uniformly fatal (median OS 1–2 years without treatment, 3–4 years with best available therapy), and has had no FDA approval specifically for PCNSL in 30+ years. The FDA and EMA offer Breakthrough Therapy Designation, Orphan Drug Designation, and accelerated approval pathways. A combination showing complete response rate improvement from ~30–40% to 60–70% in a 50-patient randomised trial would be sufficient for approval. This is an achievable Phase 2 endpoint in 12–18 months.
The combination also addresses secondary CNS lymphoma — which occurs in ~5–10% of systemic DLBCL patients and is almost uniformly fatal. This indication adds another ~15,000 cases/yr globally, extending the commercial opportunity substantially. Ibrutinib + elacridar for secondary CNS lymphoma prevention could become a standard of care companion to systemic ibrutinib therapy in high-risk DLBCL patients.
The patent cliff is addressable. Ibrutinib's compound patent expired in 2027 in most jurisdictions, but no generic entry is expected before 2032 due to the formulation and method-of-use patent estate (per AbbVie's own disclosures). A new PCNSL indication with a fixed-dose combination product (ibrutinib + bioavailable elacridar) would carry independent patent protection — method of use for CNS lymphoma — extending the franchise well beyond 2032. This creates a rare CNS lymphoma franchise that is both clinically and commercially insulated from generic competition.
The safety profile is manageable and well-characterised. Elacridar has been shown to be safe in combination with oral topotecan and doxorubicin in Phase I clinical trials, with mild-to-moderate toxicities. Ibrutinib's safety profile is well-characterised from thousands of CLL/MCL patients. The primary monitoring requirement in the combination would be haematological: ibrutinib + P-gp inhibition could increase ibrutinib exposure, so dose-finding in Phase I combination studies would establish the appropriate ibrutinib dose with elacridar. This is standard Phase Ib methodology.
Neuropsychiatric SLE (NPSLE) affects 25–75% of lupus patients and includes psychosis, cognitive dysfunction, seizures, and cerebrovascular disease. CNS inflammation driven by JAK/STAT signalling is a validated target — but current JAK inhibitors cannot adequately penetrate the BBB. Upadacitinib is confirmed as a P-gp and BCRP substrate in its prescribing information. AbbVie is already developing Rinvoq for systemic SLE — a neuropsychiatric SLE indication would be a natural extension. Elacridar co-administration could deliver therapeutic JAK1 inhibition to the CNS compartment for the first time, potentially treating CNS inflammation in lupus that is currently unaddressed. No existing approved treatment specifically targets NPSLE pathophysiology with CNS-penetrant JAK inhibition. Annual treatment costs for NPSLE are $80,000–150,000; a disease-modifying CNS therapy would command $150,000+ per year.
Projected incremental sales: $800m–1.5bn at peak · LOE: ~2032 (new indication patent protection)
Venetoclax's 15-fold inter-patient PK variability and tumour lysis syndrome risk require a 5-week inpatient dose ramp-up — one of the most onerous treatment initiation protocols in modern oncology. Venetoclax is a confirmed P-gp and BCRP substrate. Elacridar co-administration could improve venetoclax bioavailability predictability, enabling a lower, more consistent starting dose. A venetoclax + elacridar combination that enables outpatient AML initiation without TLS risk would command a substantial premium — eliminating hospitalisation costs (currently $15,000–30,000 per ramp-up admission). The key challenge is DDI management with CYP3A4 (elacridar's effect on CYP3A4 must be carefully separated from P-gp effects). A dedicated DDI pharmacology study is the required first step before any clinical development.
Projected incremental sales: $400–700m (AML safety premium) · LOE: ~2026–2028 (urgent: limited runway)
Tavapadon is AbbVie's marquee Parkinson's pipeline asset, under regulatory review following positive Phase 3 data. D1/D5 receptor occupancy in the striatum is the determinant of motor benefit. If tavapadon has any P-gp sensitivity at the BBB (plausible given its CYP3A4 dependence and the class characteristics of CNS drugs), elacridar co-administration could meaningfully increase striatal D1/D5 occupancy at a given dose — enabling lower doses that avoid the cardiovascular side effects that killed previous D1 agonist development programmes. This is a lifecycle innovation strategy: launch tavapadon alone, characterise clinical PK/PD, identify the dose-limiting cardiovascular AE threshold, then introduce tavapadon + elacridar at a lower dose with improved CNS selectivity. Timing is ideal — transporter characterisation studies can begin now in parallel with the regulatory review.
Projected incremental sales: $400–700m (differentiated "next-gen" dose-optimised Parkinson's regimen) · Dependent on initial tavapadon AE profile
Navitoclax (ABT-263) is in Phase 3 for myelofibrosis in combination with ruxolitinib. Its key limitation is BCL-xL-mediated thrombocytopenia — platelet destruction from BCL-xL inhibition. As a P-gp/BCRP substrate in the same BCL-2 inhibitor family as venetoclax, elacridar co-administration could improve navitoclax bioavailability and enable dose reduction. A lower navitoclax dose that remains efficacious for BCL-2 inhibition in malignant cells but avoids the BCL-xL platelet toxicity threshold would be transformative for the myelofibrosis indication. This would require a careful dose-finding study to establish the therapeutic window between BCL-2 efficacy and BCL-xL platelet toxicity at reduced navitoclax doses with elacridar.
Projected incremental sales: $250–500m · Dependent on navitoclax Phase 3 results and myelofibrosis market dynamics
| Priority | Combination | Indication | Mechanism | Current Drug Sales | Projected Combo Peak | LOE / Generic Date | Development Readiness |
|---|---|---|---|---|---|---|---|
| ★★ 1 — LEAD | Ibrutinib + Elacridar | Primary CNS Lymphoma (PCNSL) + Secondary CNS Lymphoma | BBB penetration: P-gp efflux elimination → 4.5–5.9× brain conc increase | $3.35bn | $800m–1.3bn (rare disease + secondary CNS lymphoma) | 2032 (effective generic entry) | Phase 1 ORR = 77% (clinical proof); elacridar combination ready for Phase Ib |
| ★ 2 | Upadacitinib + Elacridar | Neuropsychiatric SLE (NPSLE) | CNS JAK1 inhibition — confirmed P-gp/BCRP substrate; BBB penetration enhancement | $5.97bn | $800m–1.5bn (NPSLE premium) | ~2030–2032 | Preclinical; CNS transporter study required first |
| 3 | Venetoclax + Elacridar | AML — outpatient-enabling safety enhancement | Bioavailability stabilisation → safer lower starting dose → TLS risk reduction | $2.58bn | $400–700m (outpatient AML premium) | ~2026–2028 (urgent) | DDI study required; LOE pressure creates urgency |
| 4 | Tavapadon + Elacridar | Parkinson's Disease — enhanced striatal D1/D5 occupancy | Enhanced BBB penetration → lower dose → reduced cardiovascular AEs | Pre-revenue (NDA filed) | $400–700m (lifecycle innovation) | N/A — new asset; 15+ year runway | Transporter characterisation study needed; ideal timing pre-launch |
| 5 | Navitoclax + Elacridar | Myelofibrosis — thrombocytopenia-sparing regimen | Dose reduction → below BCL-xL platelet toxicity threshold | Pre-revenue (Phase 3) | $250–500m | N/A — pipeline | Dependent on Phase 3 navitoclax results; speculative until data |